Citizens JMP raised the firm’s price target on Privia Health (PRVA) to $31 from $30 and keeps an Outperform rating on the shares. Privia Health fired on all cylinders in Q3, with most key operating and financial metrics exceeding expectations, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Reports Strong Q3 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Privia Health files automatic mixed securities shelf
- Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Privia Health raises FY25 revenue view to $2.05B-$2.1B from $1.8B-$1.9B